ALX Oncology Grants Stock Options to New COO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy ALXO?
Source: Newsfilter
- Stock Option Grant: On April 16, 2026, ALX Oncology granted 800,000 stock options to new COO Jeff Knight at an exercise price of $1.68 per share, aligning with Nasdaq rules to incentivize his employment and drive business growth.
- Vesting Schedule: The stock options vest 25% on the one-year anniversary of April 13, 2026, with the remainder vesting monthly, ensuring Knight's continued service and motivation within the company.
- Pipeline Advancement: ALX Oncology is advancing its cancer treatment pipeline, with lead candidate Evorpacept showing potential as a cornerstone therapy in immuno-oncology, currently evaluated in multiple clinical trials, which is expected to positively impact future growth.
- New Drug Development: The second candidate, ALX2004, is undergoing a Phase 1 dose-escalation trial for EGFR-expressing solid tumors, and successful outcomes could further enrich the company's product line and enhance market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALXO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALXO
Wall Street analysts forecast ALXO stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.670
Low
2.00
Averages
3.33
High
4.00
Current: 1.670
Low
2.00
Averages
3.33
High
4.00
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ALX Oncology Grants Stock Options to New COO
- Stock Option Grant: On April 16, 2026, ALX Oncology granted 800,000 stock options to new COO Jeff Knight at an exercise price of $1.68 per share, aligning with Nasdaq rules to incentivize his employment and drive business growth.
- Vesting Schedule: The stock options vest 25% on the one-year anniversary of April 13, 2026, with the remainder vesting monthly, ensuring Knight's continued service and motivation within the company.
- Pipeline Advancement: ALX Oncology is advancing its cancer treatment pipeline, with lead candidate Evorpacept showing potential as a cornerstone therapy in immuno-oncology, currently evaluated in multiple clinical trials, which is expected to positively impact future growth.
- New Drug Development: The second candidate, ALX2004, is undergoing a Phase 1 dose-escalation trial for EGFR-expressing solid tumors, and successful outcomes could further enrich the company's product line and enhance market competitiveness.
See More
ALX Oncology Appoints New Chief Development Officer
- Executive Appointment: ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer effective April 13, 2026, bringing over 30 years of biopharmaceutical experience, previously at Crinetics Pharmaceuticals, where he oversaw clinical development and corporate operations, expected to drive success in clinical projects.
- Clinical Program Outlook: The evorpacept and ALX2004 clinical programs are anticipated to serve as significant catalysts in the next 12 to 18 months, with Knight's leadership expected to enhance the company's development capabilities and operational infrastructure, ensuring high-quality execution and achievement of upcoming milestones.
- Industry Expertise: Knight has held senior leadership roles at renowned biopharmaceutical companies, including Amgen and Genentech, where he gained extensive experience in oncology clinical development and regulatory affairs, providing robust support for ALX Oncology's strategic growth.
- Company Vision: Knight expressed that ALX Oncology is entering a critical growth phase with multiple opportunities to advance its pipeline, and he is excited about the company's clinical programs and data, looking forward to collaborating with the team to ensure strategic development and operational excellence.
See More
ALX Oncology Q4 2025 Earnings Call Highlights
- Executive Appointment: ALX Oncology announced the appointment of Dr. Barbara Klencke as Chief Medical Officer, succeeding her interim role since September 2025, with management highlighting the importance of this appointment during a critical inflection point for the company.
- Clinical Progress: The company reported significant advancements in the clinical development of evorpacept and ALX2004, having treated over 750 patients, with plans to advance these programs to pivotal study readiness by the end of next year, demonstrating strong execution and stable timelines.
- Successful Financing: ALX Oncology completed a $150 million financing round, strengthening its balance sheet and enabling the company to deliver more meaningful data in its ongoing clinical programs, with expectations to support operations through the first half of 2028.
- Financial Performance: The company reported a GAAP net loss of $22.8 million for Q4 2025, or $0.42 per share, a decrease from $29.2 million in the prior year period, reflecting reduced spending following pipeline prioritization efforts.
See More
ALX Oncology Q4 Earnings Miss Expectations, Shares Rise on Offering
- Earnings Report Disappointment: ALX Oncology reported a Q4 GAAP EPS of -$0.42, missing expectations by $0.06, indicating challenges in profitability that may undermine market confidence in its future earnings potential.
- Net Loss Impact: The company recorded a net loss of $22.85 million, reflecting ongoing pressures from R&D and operational expenditures, which could affect its liquidity and future investment capabilities.
- Capital Market Activity: Despite the disappointing earnings, ALX Oncology announced the pricing of an underwritten offering, resulting in a nearly 15% increase in share price, indicating a positive market response to its financing strategy that may provide essential funding support.
- Investor Engagement: ALX Oncology's presentation at the 44th Annual J.P. Morgan Healthcare Conference garnered investor interest, highlighting the company's efforts to seek new capital and strategic partnerships, potentially laying the groundwork for future growth.
See More
ALX Oncology Reports Clinical Progress and Financial Update
- Clinical Trial Progress: ALX Oncology's CD47 inhibitor Evorpacept is on track following strong execution in 2025, with multiple significant data sets and milestones anticipated in the next 12 to 18 months, showcasing the company's potential in cancer treatment.
- Biomarker Validation: Data from the ASPEN-06 gastric cancer trial and Phase 1b/2 breast cancer trial independently validate the correlation between CD47 overexpression and Evorpacept efficacy, potentially providing durable benefits for HER2-positive cancer patients and enhancing confidence in ongoing clinical trials.
- Successful Financing: The company completed a $150 million registered stock offering, extending its cash runway through the first half of 2028, ensuring the continued advancement of key clinical programs and demonstrating strong performance in the capital markets.
- Executive Appointment: Barbara Klencke, M.D. has been appointed as Chief Medical Officer on a permanent basis, expected to drive further progress in clinical development, reflecting the company's commitment to its leadership team.
See More
ALX Oncology to Participate in Multiple Biotech Summits
- Summit Participation: ALX Oncology will hold one-on-one meetings at the Wells Fargo Executive Biotech Summit on February 24-25, 2026, in Lake Tahoe, aimed at deepening investor engagement and enhancing the company's visibility in the biotech sector.
- Healthcare Conference: The company will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 9:10 AM EST in Boston, which is expected to attract significant attention from both industry insiders and investors, further driving interest in its clinical pipeline.
- Webcast Availability: The presentation at the TD Cowen conference will be available via webcast on ALX Oncology's investor section, with replays accessible for up to 90 days post-event, ensuring that investors who cannot attend live can still access critical information.
- Pipeline Progress: ALX Oncology's lead candidate, evorpacept, is being evaluated in multiple ongoing clinical trials across various cancer indications, demonstrating potential as a cornerstone therapy for immuno-oncology, thereby solidifying the company's strategic position in the biotech landscape.
See More
ALX Oncology Grants Stock Options to New COO
- Stock Option Grant: On April 16, 2026, ALX Oncology granted 800,000 stock options to new COO Jeff Knight at an exercise price of $1.68 per share, aligning with Nasdaq rules to incentivize his employment and drive business growth.
- Vesting Schedule: The stock options vest 25% on the one-year anniversary of April 13, 2026, with the remainder vesting monthly, ensuring Knight's continued service and motivation within the company.
- Pipeline Advancement: ALX Oncology is advancing its cancer treatment pipeline, with lead candidate Evorpacept showing potential as a cornerstone therapy in immuno-oncology, currently evaluated in multiple clinical trials, which is expected to positively impact future growth.
- New Drug Development: The second candidate, ALX2004, is undergoing a Phase 1 dose-escalation trial for EGFR-expressing solid tumors, and successful outcomes could further enrich the company's product line and enhance market competitiveness.
See More
ALX Oncology Appoints New Chief Development Officer
- Executive Appointment: ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer effective April 13, 2026, bringing over 30 years of biopharmaceutical experience, previously at Crinetics Pharmaceuticals, where he oversaw clinical development and corporate operations, expected to drive success in clinical projects.
- Clinical Program Outlook: The evorpacept and ALX2004 clinical programs are anticipated to serve as significant catalysts in the next 12 to 18 months, with Knight's leadership expected to enhance the company's development capabilities and operational infrastructure, ensuring high-quality execution and achievement of upcoming milestones.
- Industry Expertise: Knight has held senior leadership roles at renowned biopharmaceutical companies, including Amgen and Genentech, where he gained extensive experience in oncology clinical development and regulatory affairs, providing robust support for ALX Oncology's strategic growth.
- Company Vision: Knight expressed that ALX Oncology is entering a critical growth phase with multiple opportunities to advance its pipeline, and he is excited about the company's clinical programs and data, looking forward to collaborating with the team to ensure strategic development and operational excellence.
See More
ALX Oncology Q4 2025 Earnings Call Highlights
- Executive Appointment: ALX Oncology announced the appointment of Dr. Barbara Klencke as Chief Medical Officer, succeeding her interim role since September 2025, with management highlighting the importance of this appointment during a critical inflection point for the company.
- Clinical Progress: The company reported significant advancements in the clinical development of evorpacept and ALX2004, having treated over 750 patients, with plans to advance these programs to pivotal study readiness by the end of next year, demonstrating strong execution and stable timelines.
- Successful Financing: ALX Oncology completed a $150 million financing round, strengthening its balance sheet and enabling the company to deliver more meaningful data in its ongoing clinical programs, with expectations to support operations through the first half of 2028.
- Financial Performance: The company reported a GAAP net loss of $22.8 million for Q4 2025, or $0.42 per share, a decrease from $29.2 million in the prior year period, reflecting reduced spending following pipeline prioritization efforts.
See More
ALX Oncology Q4 Earnings Miss Expectations, Shares Rise on Offering
- Earnings Report Disappointment: ALX Oncology reported a Q4 GAAP EPS of -$0.42, missing expectations by $0.06, indicating challenges in profitability that may undermine market confidence in its future earnings potential.
- Net Loss Impact: The company recorded a net loss of $22.85 million, reflecting ongoing pressures from R&D and operational expenditures, which could affect its liquidity and future investment capabilities.
- Capital Market Activity: Despite the disappointing earnings, ALX Oncology announced the pricing of an underwritten offering, resulting in a nearly 15% increase in share price, indicating a positive market response to its financing strategy that may provide essential funding support.
- Investor Engagement: ALX Oncology's presentation at the 44th Annual J.P. Morgan Healthcare Conference garnered investor interest, highlighting the company's efforts to seek new capital and strategic partnerships, potentially laying the groundwork for future growth.
See More
ALX Oncology Reports Clinical Progress and Financial Update
- Clinical Trial Progress: ALX Oncology's CD47 inhibitor Evorpacept is on track following strong execution in 2025, with multiple significant data sets and milestones anticipated in the next 12 to 18 months, showcasing the company's potential in cancer treatment.
- Biomarker Validation: Data from the ASPEN-06 gastric cancer trial and Phase 1b/2 breast cancer trial independently validate the correlation between CD47 overexpression and Evorpacept efficacy, potentially providing durable benefits for HER2-positive cancer patients and enhancing confidence in ongoing clinical trials.
- Successful Financing: The company completed a $150 million registered stock offering, extending its cash runway through the first half of 2028, ensuring the continued advancement of key clinical programs and demonstrating strong performance in the capital markets.
- Executive Appointment: Barbara Klencke, M.D. has been appointed as Chief Medical Officer on a permanent basis, expected to drive further progress in clinical development, reflecting the company's commitment to its leadership team.
See More
ALX Oncology to Participate in Multiple Biotech Summits
- Summit Participation: ALX Oncology will hold one-on-one meetings at the Wells Fargo Executive Biotech Summit on February 24-25, 2026, in Lake Tahoe, aimed at deepening investor engagement and enhancing the company's visibility in the biotech sector.
- Healthcare Conference: The company will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 9:10 AM EST in Boston, which is expected to attract significant attention from both industry insiders and investors, further driving interest in its clinical pipeline.
- Webcast Availability: The presentation at the TD Cowen conference will be available via webcast on ALX Oncology's investor section, with replays accessible for up to 90 days post-event, ensuring that investors who cannot attend live can still access critical information.
- Pipeline Progress: ALX Oncology's lead candidate, evorpacept, is being evaluated in multiple ongoing clinical trials across various cancer indications, demonstrating potential as a cornerstone therapy for immuno-oncology, thereby solidifying the company's strategic position in the biotech landscape.
See More
